In a randomized, double-blind, placebo-controlled Phase III trial conducted across 35 sites in China with 354 patients, it was found that combining Entinostat with Exemestane significantly improved PFS in advanced HR+/HER2- breast cancer patients who had relapsed or progressed after endocrine therapy. Here, ERBB2 is linked to breast carcinoma.